UK-based drug discovery concern Astex Technology has officially opened its new, 36,000-square-foot R&D facility on the Cambridge Science Park. The new capacity, which is leased from Trinity College, includes purpose-built laboratories, offices and computational facilities.
Housing up to 150 research scientists, and with the option of being extended to cover an additional 30,000 sq ft in the future, the new facility should help Astex achieve its business objectives. "Our previous facilities became very cramped, and spilled-over into mobile units; we now have a much better environment in which to pursue our goal of developing small-molecule therapeutics using our fragment-based discovery approach," said chief executive Tim Haines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze